Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol As Treatment For Adolescents With Attention Deficit Hyperactivity Disorder

Loading news article.

Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol As Treatment For Adolescents With Attention Deficit Hyperactivity Disorder | WAPE

Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol As Treatment For Adolescents With Attention Deficit Hyperactivity Disorder

Article summary

Related companies

Comments —